First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
Telix Pharmaceuticals has commenced the first U.S. commercial doses of Pixclara® (floretyrosine F 18), the only FDA-approved radiopharmaceutical PET imaging drug for glioma. The drug aids differentiation of recurrent or progressive glioma from treatment-related changes in adult and pediatric patients, addressing a significant unmet medical need. Ma…